PRME NASDAQ
Prime Medicine, Inc.
1W: -5.7%
1M: +24.5%
3M: +16.8%
YTD: +2.3%
1Y: -32.9%
3Y: -51.1%
$4.35
+0.74 (+20.50%)
After Hours: $4.25 (-0.09, -2.18%)
Weekly Expected Move ±16.7%
$2
$3
$4
$4
$5
Credit Risk of going bust: higher than 77% of companies Debt: 14.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.10 (down 97%), Prime Medicine, Inc. would be worth roughly what it owes.
Total debt $112.5M against a stock market value of $654.8M.
Distance to default 2.85 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $56.2M (short-term plus half of long-term), stock volatility 85.8%; Altman Z'' -15.98. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.10 (down 97%), Prime Medicine, Inc. would be worth roughly what it owes.
Total debt $112.5M against a stock market value of $654.8M.
Distance to default 2.85 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $56.2M (short-term plus half of long-term), stock volatility 85.8%; Altman Z'' -15.98. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$654.8M
52W Range2.67-5.2
Volume2,508,756
Avg Volume3,730,456
Beta2.38
Dividend—
Analyst Ratings
Company Info
CEOAllan Reine
Employees146
SectorHealthcare
IndustryBiotechnology
IPO Date2022-10-20
Websiteprimemedicine.com
60 First Street
Cambridge, MA 02141
US
Cambridge, MA 02141
US
617-564-0013
About Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor proteinâa hybrid composed of a Cas protein and a reverse transcriptase enzymeâwith a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Latest News
Prime Medicine, Inc. (PRME) – What Are Brokerages Thinking About This Stock?
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
What's next for personalized mRNA cancer vaccines?
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
At a glance: stocks gapping up premarket
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Chung Wendy | A-Award | 75,000 | $3.06 | 2026-06-05 |
| Cahill Thomas | A-Award | 75,000 | $3.06 | 2026-06-05 |
| Schenkein David P | A-Award | 75,000 | $3.06 | 2026-06-05 |
| Marrazzo Jeffrey D | A-Award | 75,000 | $3.06 | 2026-06-05 |
| NELSEN ROBERT | A-Award | 75,000 | $3.06 | 2026-06-05 |